← Back to Reports

Abivax (ABVX): Ultra-Lipophilic Drug Risk – Scorpion Capital

Scorpion Capital alleges Abivax's obefazimod is ultra-lipophilic, toxic in monkey studies, and backed by retracted science and opaque China trials.

A buried 28-day monkey toxicology study allegedly halted dosing early in every treated group, citing gastrointestinal toxicity.

Abivax's experimental ulcerative colitis drug is so lipophilic that ordinary laboratory methods reportedly could not measure it, requiring specialized equipment, according to a report that compares its chemistry to DDT, dioxin, and other persistent industrial pollutants. The report alleges that obefazimod's broad, off-target chemical profile contradicts the company's claimed selective mechanism, and cites a 28-day monkey study in which dosing stopped early in every treated group due to gastrointestinal toxicity. Scorpion Capital, which holds a short position in Abivax (NASDAQ: ABVX) and says it began covering a substantial portion of that position upon publication, alleges that the company's scientific foundation rests partly on retracted literature and that its China-based Phase 3 trial operations functioned as an opaque "black hole."

Ticker: ABVX (Abivax SA)
Research Firm: Scorpion Capital
Report URL: https://scorpioncapital.com/?ref=shortreport.fyi
Report date: 2026-11-21
Position Disclosure: Short Abivax, potentially directly or through principals, affiliates, employees, consultants, clients, investors, and related entities or vehicles. The firm states it intended to begin covering a substantial portion of its short position upon publication and may have already covered most or all of it by the time readers see the report.

Published by Scorpion Capital on 2026-11-21.


The Short Report's Take

The strongest material here is empirical rather than inferential. Scorpion's own measurement of obefazimod's LogP at 6.35, its lab finding that the compound absorbs UVA light at 8.4 times the ICH photosafety threshold, and its citation of a 28-day monkey study in which the gastrointestinal tract was named the main toxicity target are each documented through direct testing or a cited study, not narrative inference. For a holder, the monkey study carries particular weight because the toxicity lands on the organ system obefazimod is meant to treat.

Much of the rest is harder to verify. The claim that obefazimod's chemistry contradicts its purported miR-124/CBC mechanism, the argument about lack of chronic-dosing precedent among approved drugs, and the allegations of inadequate Phase 3 safety surveillance and opaque China trial oversight all rest on Scorpion's own modeling or on unnamed former employees, whose accounts the firm itself says may be outdated, paraphrased, or incomplete. The allegations against co-founder Jamal Tazi and an unnamed "serial French promoter" name no specific publications, cases, or individuals in the material provided. The report cites no regulator or auditor action, and the company had not responded at publication.

The source report does not state the stock's price move or short interest on the day of publication.


Thesis

Scorpion Capital argues that obefazimod's physicochemical properties and Abivax's clinical and scientific oversight create material, undisclosed risk.

  • Extreme Lipophilicity: Obefazimod's LogP measured at 6.35, against a computed value of roughly 6, which Scorpion says predicts accumulation in cell membranes, adipose tissue, and the brain; the firm says these properties were not disclosed by Abivax.
  • Off-Target Mechanism Mismatch: The compound's measured LogP and pKa profile allegedly shows an "aberrant mass action, off-target, membrane-partitioning" pattern inconsistent with the claimed selective miR-124/CBC mechanism, and it reportedly fails multiple drug-likeness screens including the Lipinski Rule of 5, Pfizer's 3/75 rule, and the FDA Rule-of-Two.
  • No Chronic-Dosing Precedent: Of roughly 1,200 NDA approvals Scorpion reviewed over the prior decade, only 18 drugs had a LogP of at least 6, and the firm says each carried mitigants, such as orphan status, boxed warnings, or eventual withdrawal, that obefazimod lacks.
  • Photocarcinogenic Risk: Laboratory testing cited by Scorpion found obefazimod absorbs UVA radiation at 8.4 times the ICH photosafety screening threshold.
  • Buried Monkey Toxicology: A 28-day monkey study allegedly stopped dosing early in every treated group and required sacrifice of moribund animals, with the study stating the gastrointestinal tract was the main target organ of toxicity.
  • Phase 3 Safety Gaps: Former employees described to Scorpion as closely involved in safety oversight allege under-reporting, inadequate surveillance, and potentially conflicted central adjudication during Phase 3.
  • China Trial Black Hole: Former employees reportedly said China-based Phase 3 operations ran beyond their teams' visibility, and the report says listed sites included military hospitals it links to allegations of organ-sourcing or data fraud.
  • Retracted Science Foundation: Abivax investor presentations allegedly cited a mechanism-central paper that was later retracted, and Scorpion says it identified 63 retracted miR-124 papers, including eight involving STAT3.

Catalysts

  • Potential regulatory or clinical-safety scrutiny: tied to alleged phototoxicity, gastrointestinal toxicity, tissue accumulation, and Phase 3 safety-reporting concerns; no specific decision date identified in the source report.
  • Potential scrutiny of China-based Phase 3 operations and data integrity: timing not specified.
  • Potential investor or regulatory attention to retracted literature and assay reproducibility: tied to the claimed mechanism and alleged irreproducibility of foundational assays; no date given.
  • No identified dated events: no specific future filing dates, lock-up expirations, debt maturities, or regulatory decision dates are identified in the supplied text.

Company Response

The supplied text does not state that Scorpion requested comment from Abivax, Jamal Tazi, any CRO, trial site, or regulator before publication. No response from Abivax or any other named entity is reported in the source material.


Notable Details

  • Obefazimod has reportedly shown anti-parasitic and nematocidal activity and was recently studied as a potential livestock deworming drug, which Scorpion cites as evidence of broad rather than selective biological activity.
  • Obefazimod reportedly lands in "red-alert" territory under multiple named drug-likeness screens, including Pfizer's 3/75 rule, the FDA Rule-of-Two, and Waring criteria, in addition to the Lipinski Rule of 5.
  • Scorpion disclosed that it was short Abivax but intended to begin covering a substantial portion of that short position upon publication, and warned it may have already covered most or all of it by the time readers see the report.
  • Key physicochemical properties of obefazimod were, according to Scorpion's searches, not disclosed by Abivax.

"this is something even my team had no visibility…that was a big black hole for me…they just told me it's operating differently…they didn't need me or my team there…"

The report attributes this statement to a former employee describing alleged limited oversight of Abivax's China-based Phase 3 trial operations.


FAQs

What is Abivax (ABVX) and what does its lead drug obefazimod target?

Abivax is a French biotech company listed on Nasdaq that is developing obefazimod, also known as ABX464, as a treatment for ulcerative colitis. The drug's proposed mechanism involves upregulating a molecule called miR-124, which Abivax has presented as working through a selective pathway rather than broad, off-target activity.

What is Abivax SA's connection to the retracted miR-124 research cited in the report?

Abivax investor presentations reportedly cited a paper central to the company's proposed miR-124 mechanism that was later retracted, according to Scorpion Capital. The firm says it separately identified 63 retracted papers in the miR-124 research area, including eight involving STAT3, and argues the retracted chain resembles Abivax's stated anti-inflammatory mechanism.

Who is Scorpion Capital and why did it publish this report?

Scorpion Capital is an investment firm led by founder and chief investment officer Gurkirat Kahlon that discloses a short position in Abivax. The firm says the report follows an 11-month investigation combining interviews, literature review, and independent laboratory testing, and it states it began covering a substantial portion of its short position upon publication.

What does LogP mean and why does the 6.35 figure matter for obefazimod?

LogP is a measure of how strongly a compound prefers fat-like (lipid) environments over water-based ones, with higher numbers indicating greater lipophilicity. Scorpion says its CRO measured obefazimod's LogP at 6.35, a level the firm compares to persistent industrial pollutants like DDT and dioxin, and argues this predicts accumulation in membranes, fat tissue, and the brain rather than the selective activity Abivax has described.

What happened in the 28-day monkey toxicology study cited in the report?

Scorpion says the study found dosing was stopped early in every treated group and that moribund animals had to be sacrificed. The study is quoted as stating that the gastrointestinal tract was the main target organ of ABX464 toxicity, which the report flags as notable given obefazimod is being developed for a gastrointestinal disease.

Did Abivax respond to the allegations in the Scorpion Capital report?

The source report does not indicate that Scorpion requested comment from Abivax, and no response from the company is reported in the material reviewed.

What did former employees say about Abivax's China-based clinical trials?

Former employees described to Scorpion said the company's China-based Phase 3 operations ran outside the visibility of their own teams, calling it a "black hole." The report also says some listed trial sites, including military hospitals, have been linked to separate allegations of organ-sourcing or data-fraud controversies, though it does not establish a direct allegation against a specific Abivax site.


Disclaimer: This summary is not primary research and does not constitute investment advice. It is a brief overview of a detailed equity research report authored by the firm, organization, or source referenced in this article or at https://scorpioncapital.com/, which contains extensive evidence, regulatory filings, and analysis; readers are encouraged to review the full report there for a comprehensive understanding. The content provided in this publication is not authored or originated by us — we act solely as a distributor and do not endorse, verify, or take responsibility for the accuracy, completeness, or reliability of the information presented. This publication is for informational purposes only and should not be construed as legal, business, investment, or tax advice. Always conduct independent due diligence and consult qualified professionals before making any decisions based on the information contained herein. We disclaim all liability for any loss or damage arising from reliance on third-party content, and the views expressed are solely those of the respective source and do not necessarily reflect our own.